@article{MTMT:2557678,
	title = {Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial.},
	url = {https://m2.mtmt.hu/api/publication/2557678},
	author = {Polgár, Csaba and Fodor, János and Major, Tibor and Sulyok, Z and Kásler, Miklós},
	doi = {10.1016/j.radonc.2013.05.008},
	journal-iso = {RADIOTHER ONCOL},
	journal = {RADIOTHERAPY AND ONCOLOGY},
	volume = {108},
	unique-id = {2557678},
	issn = {0167-8140},
	abstract = {BACKGROUND AND PURPOSE: To report the long-term results of a single-institution randomized study comparing the results of breast-conserving treatment with partial breast irradiation (PBI) or conventional whole breast irradiation (WBI). PATIENTS AND METHODS: Between 1998 and 2004, 258 selected women with pT1 pN0-1mi M0, grade 1-2, non-lobular breast cancer without the presence of extensive intraductal component and resected with negative margins were randomized after BCS to receive 50 Gy WBI (n=130) or PBI (n=128). The latter consisted of either 7 x 5.2 Gy high-dose-rate (HDR) multi-catheter brachytherapy (BT; n=88) or 50 Gy electron beam (EB) irradiation (n=40). Primary endpoint was local recurrence (LR) as a first event. Secondary endpoints were overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and cosmetic results. RESULTS: After a median follow up of 10.2 years, the ten-year actuarial rate of LR was 5.9% and 5.1% in PBI and WBI arms, respectively (p=0.77). There was no significant difference in the ten-year probability of OS (80% vs 82%), CSS (94% vs 92%), and DFS (85% vs 84%), either. The rate of excellent-good cosmetic result was 81% in the PBI, and 63% in the control group (p<0.01). CONCLUSIONS: Partial breast irradiation delivered by interstitial HDR BT or EB for a selected group of early-stage breast cancer patients produces similar ten-year results to those achieved with conventional WBI. Significantly better cosmetic outcome can be achieved with HDR BT implants compared with the outcome after WBI.},
	year = {2013},
	eissn = {1879-0887},
	pages = {197-202},
	orcid-numbers = {Polgár, Csaba/0000-0001-7245-0762; Major, Tibor/0000-0002-4672-6910; Kásler, Miklós/0000-0002-7235-8787}
}

@article{MTMT:2571279,
	title = {Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery. recommendations of the Groupe Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)},
	url = {https://m2.mtmt.hu/api/publication/2571279},
	author = {Polgár, Csaba and Van, Limbergen E and Potter, R and Kovacs, G and Polo, A and Lyczek, J and Hildebrandt, G and Niehoff, P and Guinot, JL and Guedea, F and Johansson, B and Ott, OJ and Major, Tibor and Strnad, V and the, GEC-ESTRO breast cancer working group},
	doi = {10.1016/j.radonc.2010.01.014},
	journal-iso = {RADIOTHER ONCOL},
	journal = {RADIOTHERAPY AND ONCOLOGY},
	volume = {94},
	unique-id = {2571279},
	issn = {0167-8140},
	abstract = {PURPOSE: To give recommendations on patient selection criteria for the use of accelerated partial-breast irradiation (APBI) based on available clinical evidence complemented by expert opinion. METHODS AND MATERIALS: Overall, 340 articles were identified by a systematic search of the PubMed database using the keywords "partial-breast irradiation" and "APBI". This search was complemented by searches of reference lists of articles and handsearching of relevant conference abstracts and book chapters. Of these, 3 randomized and 19 prospective non-randomized studies with a minimum median follow-up time of 4 years were identified. The authors reviewed the published clinical evidence on APBI, complemented by relevant clinical and pathological studies of standard breast-conserving therapy and, through a series of personal communications, formulated the recommendations presented in this article. RESULTS: The GEC-ESTRO Breast Cancer Working Group recommends three categories guiding patient selection for APBI: (1) a low-risk group for whom APBI outside the context of a clinical trial is an acceptable treatment option; including patients ageing at least 50 years with unicentric, unifocal, pT1-2 (<or=30 mm) pN0, non-lobular invasive breast cancer without the presence of an extensive intraductal component (EIC) and lympho-vascular invasion (LVI) and with negative surgical margins of at least 2mm, (2) a high-risk group, for whom APBI is considered contraindicated; including patients ageing <or=40 years; having positive margins, and/or multicentric or large (>30 mm) tumours, and/or EIC positive or LVI positive tumours, and/or 4 or more positive lymph nodes or unknown axillary status (pNx), and (3) an intermediate-risk group, for whom APBI is considered acceptable only in the context of prospective clinical trials. CONCLUSIONS: These recommendations will provide a clinical guidance regarding the use of APBI outside the context of a clinical trial before large-scale randomized clinical trial outcome data become available. Furthermore they should promote further clinical research focusing on controversial issues in the treatment of early-stage breast carcinoma.},
	keywords = {Europe; Age Factors; Adult; Female; Middle Aged; Humans; Prognosis; Societies, Medical; Breast Neoplasms/*radiotherapy; Mastectomy, Segmental; *Patient Selection; *Radiotherapy},
	year = {2010},
	eissn = {1879-0887},
	pages = {264-273},
	orcid-numbers = {Polgár, Csaba/0000-0001-7245-0762; Major, Tibor/0000-0002-4672-6910}
}